TriReme Medical, Inc., a Pleasanton, California-based developer of innovative catheters and stents for the treatment of complex vascular disease, closed a $17m Series D financing round.
The investment was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments, with strong participation from existing backers Three Arch Partners and Adams Street Partners.
As also stated by Eitan Konstantino, Ph.D., President and CEO of the company, the new capital will allow TriReme to ramp up its commercial activities worldwide, continue to develop internal R&D programs and pursue key regulatory approvals for its products in large markets such as the US, Japan, and China.
TriReme Medical is dedicated to the development, manufacturing, and commercialization of innovative percutaneous devices for the treatment of complex coronary and peripheral arterial disease.
Its portfolio currently includes two CE marked products:
– the Antares® Coronary Stent System , a proprietary main vessel stent that adapts to a broad variety of bifurcation lesions to produce predictable results during provisional stenting.
– the Glider™ PTCA Balloon Catheter, a dilatation catheter designed to overcome the limitations of conventional balloon catheters in treating complex disease.